<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Khandakar GI</submitter><funding>Ministry of Education, Culture, Sports, Science and Technology</funding><funding>Japan Society for the Promotion of Science</funding><pagination>702</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8869916</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(4)</volume><pubmed_abstract>The mitogen-activated protein kinase (MAPK)/ERK and phosphatidylinositol-3 kinase (PI3K)/AKT pathways are dysregulated in various human cancers, including pancreatic ductal adenocarcinoma (PDAC), which has a very poor prognosis due to its lack of efficient therapies. We have previously identified ACAGT-007a (GT-7), an anti-cancer compound that kills ERK-active melanoma cells by inducing ERK-dependent apoptosis. Here, we investigated the apoptosis-inducing effect of GT-7 on three PDAC cell lines and its relevance with the MAPK/ERK and PI3K/AKT signaling pathways. GT-7 induced apoptosis in PDAC cells with different KRAS mutations (MIA-Pa-Ca-2 (KRAS G12C), T3M4 (KRAS Q61H), and PANC-1 (KRAS G12D)), being T3M4 most susceptible, followed by MIA-Pa-Ca-2, and PANC-1 was most resistant to apoptosi</pubmed_abstract><journal>Cells</journal><pubmed_title>ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.</pubmed_title><pmcid>PMC8869916</pmcid><funding_grant_id>JPS1411037</funding_grant_id><funding_grant_id>JP19H03376</funding_grant_id><funding_grant_id>JP20K06494</funding_grant_id><pubmed_authors>Satoh R</pubmed_authors><pubmed_authors>Fujitani K</pubmed_authors><pubmed_authors>Tanabe G</pubmed_authors><pubmed_authors>Nishio K</pubmed_authors><pubmed_authors>Takasaki T</pubmed_authors><pubmed_authors>Sakai K</pubmed_authors><pubmed_authors>Sugiura R</pubmed_authors><pubmed_authors>Khandakar GI</pubmed_authors></additional><is_claimable>false</is_claimable><name>ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.</name><description>The mitogen-activated protein kinase (MAPK)/ERK and phosphatidylinositol-3 kinase (PI3K)/AKT pathways are dysregulated in various human cancers, including pancreatic ductal adenocarcinoma (PDAC), which has a very poor prognosis due to its lack of efficient therapies. We have previously identified ACAGT-007a (GT-7), an anti-cancer compound that kills ERK-active melanoma cells by inducing ERK-dependent apoptosis. Here, we investigated the apoptosis-inducing effect of GT-7 on three PDAC cell lines and its relevance with the MAPK/ERK and PI3K/AKT signaling pathways. GT-7 induced apoptosis in PDAC cells with different KRAS mutations (MIA-Pa-Ca-2 (KRAS G12C), T3M4 (KRAS Q61H), and PANC-1 (KRAS G12D)), being T3M4 most susceptible, followed by MIA-Pa-Ca-2, and PANC-1 was most resistant to apoptosi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2026-06-19T03:20:33.536Z</modification><creation>2025-04-19T09:45:29.734Z</creation></dates><accession>S-EPMC8869916</accession><cross_references><pubmed>35203351</pubmed><doi>10.3390/cells11040702</doi></cross_references></HashMap>